Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)

Clinical trial NCT00267748 · COMPLETED

Trial details

NCT number: NCT00267748
Sponsor: Pfizer
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Carcinoma, Renal Cell

Start date: 2005-12-01
Primary completion: 2010-06-01
Enrollment: 317

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.